Chronic News and Research

RSS

FDA approves Gilead’s Stribild to treat HIV-1 infection

The U.S. Food and Drug Administration today approved Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), a new once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.

28 Aug 2012

Women with severe aortic stenosis less likely to die following TAVI

Women with severe aortic stenosis are 40% less likely to die after transcatheter aortic valve implantation (TAVI) than men, reveals the latest data from the largest study to date of gender differences in outcomes after TAVI.

27 Aug 2012

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz, Inc. today announced the acquisition of CUVPOSA (glycopyrrolate) oral solution for pediatric chronic severe drooling associated with neurologic conditions such as cerebral palsy.

27 Aug 2012

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet strength of EXALGO (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

FDA approves Mallinckrodt's EXALGO (32 mg) sNDA to manage opioid-related pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) filed by Mallinckrodt Inc., a subsidiary of Covidien plc, for the 32 mg dose strength of EXALGO (hydromorphone HCl) Extended-Release Tablets (CII), for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

Study explores gender-related differences in patients hospitalized for acute heart failure

Women with acute heart failure have similar in-hospital mortality to men but are less treated in the real world, according to results from the global ALARM-HF registry presented today at the ESC Congress 2012. The findings were presented by Dr John T. Parissis from Greece.

27 Aug 2012

Patients with psoriasis are at high risk of new-onset diabetes mellitus

Patients with psoriasis are at high risk of new-onset diabetes mellitus, according to research presented at ESC Congress 2012.

27 Aug 2012

Belly fat linked with increased risk of cardiovascular death in normal weight individuals

Normal weight individuals who carry weight concentrated in their belly have a higher death risk than obese individuals, according to research presented at ESC Congress 2012.

27 Aug 2012

New data from Boehringer Ingelheim and Pfizer's tiotropium clinical studies on asthma, COPD

New data to be presented at the Annual Congress of the European Respiratory Society (ERS 2012), in Vienna, Austria, will shed light on the current and potential future role of tiotropium, the first once-daily long-acting inhaled anticholinergic for patients with Chronic Obstructive Pulmonary Disease (COPD).

27 Aug 2012

Mexican-Americans with ancestral links have higher insulin resistance levels

Mexican-Americans with an ancestral link to Amerindian tribes were found to have higher insulin resistance levels, which is an indication of several chronic conditions such as type 2 diabetes, according to research by The University of Texas Health Science Center at Houston (UTHealth).

26 Aug 2012

MRC awards grant to design new drug for treatment of chronic pain

Scientists at the University of Liverpool and the Royal Liverpool University Hospital have been awarded -1.4 million to design a new drug for the treatment of chronic pain.

24 Aug 2012

Novira secures $23M in Series A financing to support antiviral development for HBV, HIV

Novira Therapeutics Inc. today announced it has secured $23 million in Series A financing to support the development of its capsid-targeting antivirals for the treatment of chronic hepatitis B (HBV) and HIV infections.

24 Aug 2012

New method can differentiate between breast cancer patients with good and poor prognosis

It is now possible to identify aggressive breast cancers by interpreting the mathematical patterns in the cancer genome. Researchers at the University of Oslo, Norway (UiO) have developed a completely new method for differentiating between breast cancer patients with high and low risks of dying from the illness.

24 Aug 2012

Study helps explain how human airways clear sticky mucus out of the lungs

A runny nose and a wet cough caused by a cold or an allergy may not feel very good. But human airways rely on sticky mucus to expel foreign matter, including toxic and infectious agents, from the body.

24 Aug 2012

Novel questionnaire reliably assesses antiepileptic adverse effects in children

The adverse effects of antiepileptic drugs can be reliably measured in children from across the epilepsy spectrum in clinical and research settings with the novel Pediatric Epilepsy Side Effects Questionnaire, say US scientists.

23 Aug 2012

Food insecure HIV-infected poor people more likely to visit ERs

UCSF researchers found that poor HIV-infected individuals living in San Francisco are significantly more likely to visit emergency rooms and to have hospital stays if they lack access to food of sufficient quality and quantity for a healthy life.

23 Aug 2012

CMS announces participation of PCPs in Comprehensive Primary Care Initiative

The American College of Physicians (ACP) today praised the Centers for Medicare and Medicaid Services (CMS) for its announcement of primary care practices to participate in a historic public-private partnership to strengthen primary care, the Comprehensive Primary Care Initiative (CPCI).

23 Aug 2012